Free Trial

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo

NMTR vs. NBY, VRAX, SPRC, GRI, VAXX, ADIL, CANF, PALI, LIPO, and EVAX

Should you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include NovaBay Pharmaceuticals (NBY), Virax Biolabs Group (VRAX), SciSparc (SPRC), GRI Bio (GRI), Vaxxinity (VAXX), Adial Pharmaceuticals (ADIL), Can-Fite BioPharma (CANF), Palisade Bio (PALI), Lipella Pharmaceuticals (LIPO), and Evaxion A/S (EVAX). These companies are all part of the "pharmaceutical products" industry.

9 Meters Biopharma vs. Its Competitors

9 Meters Biopharma (NASDAQ:NMTR) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled NovaBay Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
NovaBay Pharmaceuticals Neutral

9 Meters Biopharma has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. 9 Meters Biopharma's return on equity of -584.97% beat NovaBay Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41%

9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

NovaBay Pharmaceuticals has a consensus target price of $0.85, indicating a potential upside of 26.41%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NovaBay Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NovaBay Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. NovaBay Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
NovaBay Pharmaceuticals$9.78M0.40-$9.64M-$53.72-0.01

Summary

NovaBay Pharmaceuticals beats 9 Meters Biopharma on 8 of the 13 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Metric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$1.04M$136.79M$5.69B$9.50B
Dividend YieldN/A3.74%4.58%4.01%
P/E Ratio-0.023.7528.1020.05
Price / SalesN/A4,471.55432.4490.07
Price / CashN/A13.1936.2258.56
Price / BookN/A42.328.665.87
Net Income-$43.77M-$90.99M$3.25B$258.55M

9 Meters Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/A-0.0220
NBY
NovaBay Pharmaceuticals
1.5773 of 5 stars
$0.69
0.0%
$0.85
+23.2%
-65.3%$4.01M$9.78M-0.0130
VRAX
Virax Biolabs Group
2.4989 of 5 stars
$0.91
-1.7%
$3.00
+229.7%
-15.5%$3.95M$6.33K0.005Positive News
SPRC
SciSparc
0.8637 of 5 stars
$7.31
-5.1%
N/A-30.1%$3.91M$1.31M0.004
GRI
GRI Bio
2.9111 of 5 stars
$1.82
-1.6%
$22.00
+1,108.8%
-90.8%$3.90MN/A-0.161
VAXX
Vaxxinity
N/A$0.03
+29,900.0%
N/A-83.3%$3.80MN/A-0.0790
ADIL
Adial Pharmaceuticals
2.9093 of 5 stars
$0.36
-2.0%
$8.00
+2,109.9%
-56.1%$3.77MN/A-0.2520Analyst Upgrade
Gap Down
CANF
Can-Fite BioPharma
1.989 of 5 stars
$1.05
+1.9%
$14.00
+1,233.3%
-71.7%$3.70M$674K-0.588
PALI
Palisade Bio
2.7405 of 5 stars
$0.76
-0.6%
$12.00
+1,478.9%
-72.2%$3.65MN/A-0.1110
LIPO
Lipella Pharmaceuticals
1.2649 of 5 stars
$0.80
+6.5%
N/A-80.2%$3.57M$536.36K-0.204Gap Up
EVAX
Evaxion A/S
2.7659 of 5 stars
$2.53
-5.4%
$10.00
+296.0%
-81.3%$3.55M$3.34M-2.1960News Coverage

Related Companies and Tools


This page (NASDAQ:NMTR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners